189 related articles for article (PubMed ID: 29439670)
1. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
Thomas SK; Cha SC; Smith DL; Kim KH; Parshottam SR; Rao S; Popescu M; Lee VY; Neelapu SS; Kwak LW
BMC Cancer; 2018 Feb; 18(1):187. PubMed ID: 29439670
[TBL] [Abstract][Full Text] [Related]
2. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
Cha SC; Qin H; Sakamaki I; Kwak L
Methods Mol Biol; 2014; 1139():289-303. PubMed ID: 24619688
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
4. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency.
Guo JH; Fan MW; Sun JH; Jia R
Int Immunopharmacol; 2009 Jul; 9(7-8):925-30. PubMed ID: 19348967
[TBL] [Abstract][Full Text] [Related]
5. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccination: antigen presentation and the induction of immunity.
Shedlock DJ; Weiner DB
J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
[TBL] [Abstract][Full Text] [Related]
7. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.
Igoucheva O; Grazzini M; Pidich A; Kemp DM; Larijani M; Farber M; Lorton J; Rodeck U; Alexeev V
Gene Ther; 2013 Sep; 20(9):939-48. PubMed ID: 23552473
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.
Meleshko AN; Petrovskaya NA; Savelyeva N; Vashkevich KP; Doronina SN; Sachivko NV
Hum Vaccin Immunother; 2017 Jun; 13(6):1-6. PubMed ID: 28272989
[TBL] [Abstract][Full Text] [Related]
9. Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities.
Luo K; Zhang H; Zavala F; Biragyn A; Espinosa DA; Markham RB
PLoS One; 2014; 9(3):e90413. PubMed ID: 24599116
[TBL] [Abstract][Full Text] [Related]
10. New strategies for vaccination and imunomodulation in NHL.
Stevenson FK; Zhu D; Rice J
Ann Hematol; 2001; 80 Suppl 3():B132-4. PubMed ID: 11757697
[TBL] [Abstract][Full Text] [Related]
11. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
12. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.
Fredriksen AB; Bogen B
Blood; 2007 Sep; 110(6):1797-805. PubMed ID: 17540847
[TBL] [Abstract][Full Text] [Related]
13. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
14. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
15. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
17. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
Ferrone CR; Perales MA; Goldberg SM; Somberg CJ; Hirschhorn-Cymerman D; Gregor PD; Turk MJ; Ramirez-Montagut T; Gold JS; Houghton AN; Wolchok JD
Clin Cancer Res; 2006 Sep; 12(18):5511-9. PubMed ID: 17000687
[TBL] [Abstract][Full Text] [Related]
18. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
Hurvitz SA; Timmerman JM
Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
[TBL] [Abstract][Full Text] [Related]
19. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
20. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
Singh G; Parker S; Hobart P
Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
